Research Atlas · source screening

Zilucoplan

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Title-search results

44

Shown with stable PMIDs

24

Search recorded

2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Zilucoplan"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

1. Comparative Efficacy of Zilucoplan Versus Intravenous Immunoglobulin, Eculizumab, and Ravulizumab Using Matching-Adjusted Indirect Comparisons.

   Neurol Ther · 2026 Sep 24 · PMID 42786374 · DOI 10.1007/s40120-026-01021-y

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

2. A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis.

   JAAD Case Rep · 2026 Sep · PMID 42604018 · DOI 10.1016/j.jdcr.2026.06.066

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

3. Fibrosing Skin Disorder Associated With Zilucoplan.

   JAMA Dermatol · 2026 Aug 19 · PMID 42616530 · DOI 10.1001/jamadermatol.2026.2321

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

4. Zilucoplan-Associated Morpheaform Skin Changes and Methotrexate and UVA1 Phototherapy.

   JAMA Dermatol · 2026 Aug 19 · PMID 42616491 · DOI 10.1001/jamadermatol.2026.2314

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

5. Case Report: Zilucoplan in refractory myasthenic crisis and its prodromal stages: a novel therapeutic perspective.

   Front Neurosci · 2026 · PMID 42591413 · DOI 10.3389/fnins.2026.1886744

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

6. Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences.

   Acta Neurol Belg · 2026 Jul 17 · PMID 42467314 · DOI 10.1007/s13760-026-03109-6

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

7. Zilucoplan is effective for ravulizumab-refractory generalized myasthenia gravis with the C5 p.Arg885His variant: a case report.

   Neuromuscul Disord · 2026 Apr · PMID 41771246 · DOI 10.1016/j.nmd.2026.106386

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

8. Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France.

   J Neuromuscul Dis · 2026 Mar 29 · PMID 41904994 · DOI 10.1177/22143602261437792

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

9. Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

   J Neurol Sci · 2026 Mar 15 · PMID 41653661 · DOI 10.1016/j.jns.2026.125759

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

10. Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

    J Neurol Sci · 2026 Mar 15 · PMID 41604997 · DOI 10.1016/j.jns.2026.125768

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

11. Comments on ZILU25: Real-world efficacy of Zilucoplan in generalized myasthenia gravis.

    J Neurol Sci · 2026 Feb 15 · PMID 41512541 · DOI 10.1016/j.jns.2026.125741

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

12. Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan.

    J Dtsch Dermatol Ges · 2026 Feb · PMID 41058183 · DOI 10.1111/ddg.15919

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

13. Rapid Symptomatic Improvement and Long-Term Minimal Symptom Expression in a Myasthenia Gravis Patient Treated With Zilucoplan Without Maintenance Cholinesterase Inhibitors, Corticosteroids, or Immunosuppressants: A Case Report.

    Cureus · 2026 Jan · PMID 41769457 · DOI 10.7759/cureus.102589

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

14. Discovery of Zilucoplan: A Complement C5 Inhibitor for Treatment of Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (gMG).

    J Med Chem · 2025 Dec 25 · PMID 41379101 · DOI 10.1021/acs.jmedchem.5c02537

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

15. Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

    J Neurol Sci · 2025 Dec 15 · PMID 41314023 · DOI 10.1016/j.jns.2025.125671

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

16. Zilucoplan in myasthenic crisis refractory to conventional treatment: a report of two cases.

    Acta Neurol Belg · 2025 Dec · PMID 40892124 · DOI 10.1007/s13760-025-02860-6

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

17. Zilucoplan as a fast-acting treatment for severe myasthenic exacerbation: A case series.

    Rev Neurol (Paris) · 2025 Sep · PMID 40685269 · DOI 10.1016/j.neurol.2025.06.010

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

18. [Myasthenia Gravis Treated with Zilucoplan Prior to Extended Transsternal Thymectomy for the Prevention of Myasthenic Crisis: A Case Report].

    Brain Nerve · 2025 Aug · PMID 40825554 · DOI 10.11477/mf.188160960770080921

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

19. Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study.

    J Neurol Sci · 2025 Jul 15 · PMID 40450840 · DOI 10.1016/j.jns.2025.123550

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

20. Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study.

    Ther Adv Neurol Disord · 2025 · PMID 40620733 · DOI 10.1177/17562864251347283

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

21. Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.

    J Neurol · 2025 Jun 12 · PMID 40504283 · DOI 10.1007/s00415-025-13113-0

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

22. Subcutaneous zilucoplan: Evaluation of reproductive toxicology.

    Reprod Toxicol · 2025 May · PMID 40049247 · DOI 10.1016/j.reprotox.2025.108877

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

23. Zilucoplan for Successful Early Weaning From Mechanical Ventilation and Avoiding Tracheostomy in an 85-Year-Old Woman Experiencing Myasthenic Crisis: A Case Report.

    Cureus · 2025 Mar · PMID 40190980 · DOI 10.7759/cureus.80203

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

24. Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

    JAMA Netw Open · 2025 Feb 3 · PMID 39960672 · DOI 10.1001/jamanetworkopen.2024.59058

    Source metadata only · evidence grade unassigned · scientific conclusions pending review